As of Thursday close, Taysha Gene Therapies Inc.’s (NASDAQ:TSHA) stock was down -$0.08, moving down -2.44 percent to $3.20. The average number of shares traded per day over the past five days has been 5,777,160 shares. 4 times new highs have been achieved over the past 5 days, with a $0.86 gain in that time frame. In the last twenty days, the average volume was 13,237,045, while in the previous 50 days, it was 5,423,694.
Since last month, TSHA stock rose 371.42%. Shares of the company fell to $0.65 on 08/01/23, the lowest level in the past month. A 52-week high of $4.06 was reached on 08/30/23 after having rallying from a 52-week low of $0.50. Since the beginning of this year, TSHA’s stock price has risen by 41.59% or $0.94, and marked a new high 6 times. However, the stock has declined by -21.14% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
TSHA stock investors should be aware that Taysha Gene Therapies Inc. (TSHA) stock had its last reported insider trading activity 8 days ago on Aug 24. Alam Kamran, the Chief Financial Officer of the company, disposed of 33,000 shares for $2.33 on Aug 24. It resulted in a $76,890 divestment by the insider. Manning Paul B added 16,466,667 shares at an average price of $0.90 on Aug 16. The insider now owns 16,466,667 shares following the transaction. On Aug 16, Chief Executive Officer Nolan Sean P. bought 444,444 shares at $0.90 apiece. The transaction was valued at $400,000.
Financial Health
In the three months ended June 29, Taysha Gene Therapies Inc.’s quick ratio stood at 1.10, while its current ratio was 1.10, showing that the company is able to pay off its debt. Based on annual data, TSHA earned $164.95 million in gross profit and brought in $2.5 million in revenue.
In Taysha Gene Therapies Inc.’s quarter-end financial report for June 29, it reported total debt of $38.35 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. TSHA’s revenue rose 100.0% to $4.71 million during the quarter, while net income inched up to $2.4 million. While analysts expected Taysha Gene Therapies Inc. to report -$0.31 quarterly earnings, the actual figure was -$0.38 per share, beating the consensus estimate by -22.60%. During the quarter, the company generated -$23.04 million in EBITDA. The liabilities of Taysha Gene Therapies Inc. were 118.66 million at the end of its most recent quarter ended June 29, and its total debt was $60.44 million. The value of shareholders’ equity is $64.47 million.
Technical Picture
This quick technical analysis looks at Taysha Gene Therapies Inc.’s (TSHA) price momentum. With a historical volatility rate of 198.97%, the RSI 9-day stood at 81.02% on 31 August.
With respect to its five-day moving average, the current Taysha Gene Therapies Inc. price is up by +36.75% percent or $0.86. At present, TSHA shares trade +364.31% above its 20-day simple moving average and +381.20% percent above its 100-day simple moving average. However, the stock is currently trading approximately +357.08% above its SMA50 and +46.79% above its SMA200.
Stochastic coefficient K was 90.72% and Stochastic coefficient D was 88.96%, while ATR was 0.40. Given the Stochastic reading of 84.17% for the 14-day period, the RSI (14) reading has been calculated as 81.07%. As of today, the MACD Oscillator reading stands at 0.74, while the 14-day reading stands at 0.93.
Analyst Ratings
Taysha Gene Therapies Inc. downgraded its rating on Taysha Gene Therapies Inc. (NASDAQ: TSHA) to a Hold in a note to investors on February 01, 2023. The analysts firm previously had a Buy rating on the stock.Taysha Gene Therapies Inc. (TSHA) has been rated Buy by analysts. According to 0 brokerage firms, TSHA is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Taysha Gene Therapies Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $6.00, the current consensus forecast for the stock is $2.00 – $8.00. Based on these forecasts, analysts predict Taysha Gene Therapies Inc. (TSHA) will achieve an average price target of $5.72.
